Clinical study published regarding XNK Therapeutics’ NK cell-based product
XNK Therapeutics AB (“XNK”) today announced that the first-in-human Phase I study ACP-001, performed at the Karolinska University Hospital in Huddinge, Sweden, has been published in Cell Reports Medicine. The study demonstrates that XNK’s autologous natural killer (NK) cell-based immunotherapy is feasible. Furthermore, it shows a good safety profile and promising efficacy data as consolidation treatment following autologous stem cell transplantation in patients newly diagnosed with multiple myeloma.“XNK is focused on the clinical development of autologous natural killer cell-based products